Medicare AdvantagePrior AuthMedium impact
Komzifti™ (ziftomenib) (New)
Humana·Hematology, Oncology·Medicare Advantage
Effective date
Mar 25, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has established a new prior authorization policy for Komzifti (ziftomenib), a specialty medication for treating relapsed or refractory acute myeloid leukemia (AML) with NPM1 mutations. This requires prior auth approval before prescribing, with specific criteria including confirmed NPM1 mutation and no other treatment alternatives.
Action Required
Before March 25, 2026: Billing team must update prior authorization requirements for Komzifti (ziftomenib) prescriptions for Humana Medicare Advantage members. Providers must obtain prior auth by confirming patient has relapsed/refractory AML with NPM1 mutation and no other treatment alternatives. Visit www.humana.com/PAL for medical billing codes and preauthorization forms.